EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter

Feng Shi, Min Zhou, Li Shang, Qianqian Du, Yueshuo Li, Longlong Xie, Xiaolan Liu, Min Tang, Xiangjian Luo, Jia Fan, Jian Zhou, Qiang Gao, Shuang Jian Qiu, Weizhong Wu, Xin Zhang, Ann M. Bode, Ya Cao

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

EBV infection is a recognized epigenetic driver of carcinogenesis. We previously showed that EBV could protect cancer cells from TNF-induced necroptosis. This study aims to explore the epigenetic mechanisms allowing cancer cells with EBV infection to escape from RIP3-dependent necroptosis. Methods: Data from the TCGA database were used to evaluate the prognostic value of RIP3 promoter methylation and its expression. Western blotting, real-time PCR, and immunochemistry were conducted to investigate the relationship between LMP1 and RIP3 in cell lines and NPC tissues. BSP, MSP and hMeDIP assays were used to examine the methylation level. Induction of necroptosis was detected by cell viability assay, p-MLKL, and Sytox Green staining. Results: RIP3 promoter hypermethylation is an independent prognostic factor of poorer disease-free and overall survival in HNSCC patients, respectively. RIP3 is down-regulated in NPC (a subtype of HNSCC). EBV(LMP1) suppresses RIP3 expression by hypermethylation of the RIP3 promoter. RIP3 protein expression was inversely correlated with LMP1 expression in NPC tissues. Restoring RIP3 expression in EBV(LMP1)-positive cells inhibits xenograft tumor growth. The accumulation of fumarate and reduction of α−KG in EBV(LMP1)-positive cells led to RIP3 silencing due to the inactivation of TETs. Decreased FH activity caused fumarate accumulation, which might be associated with its acetylation. Incubating cells with fumarate protected NPC cells from TNF-induced necroptosis. Conclusion: These results demonstrate a pathway by which EBV(LMP1)-associated metabolite changes inhibited necroptosis signaling by DNA methylation, and shed light on the mechanism underlying EBV-related carcinogenesis, which may provide new options for cancer diagnosis and therapy.

Original languageEnglish (US)
Pages (from-to)2424-2438
Number of pages15
JournalTheranostics
Volume9
Issue number9
DOIs
StatePublished - 2019

Bibliographical note

Funding Information:
We thank Prof. Sai Wah Tsao (University of Hong Kong, Hong Kong SAR, China) for providing the human NPC cell lines and the immortalized human nasopharyngeal epithelial cell lines; Prof. Yongguang Tao (Central South University, Changsha, China) for suggestions and discussions. This study was supported by National Natural Science Foundation of China (81430064, 81602402, 81874172), China Postdoctoral Science Foundation funded project (2017M612595), Hunan Provincial Natural Science Foundation of China (2018JJ3700), the Fundamental Research Funds for the Central Universities (502042004) and the Open-End Fund for the Valuable and Precision Instruments of Central South University (CSUZC201744).

Publisher Copyright:
© Ivyspring International Publisher.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Keywords

  • Epstein-Barr virus
  • Fumarate
  • Nasopharyngeal carcinoma
  • Necroptosis
  • Receptor-interacting protein 3

Fingerprint Dive into the research topics of 'EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter'. Together they form a unique fingerprint.

Cite this